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Abstract 
 Most human papillomaviruses cause inapparent infections, subtly affecting 
epithelial homeostasis to ensure genome persistence in the epithelial basal layer.  
As with conspicuous papillomas, these self-limiting lesions shed viral particles to 
ensure population-level maintenance, and depend on a balance between viral gene 
expression, immune cell stimulation, and immune surveillance for persistence.  The 
complex immune evasion strategies, characteristic of high-risk HPV types, also 
allow the deregulated viral gene expression that underlies neoplasia.  Neoplasia 
occurs at particular epithelial sites where vulnerable cells such as the reserve or 
cuboidal cells of the cervical transformation zone are found. Beta papillomavirus 
infection can also predispose to the development of cancers in individuals with 
immune deficiencies. The host control of HPV infections thus involves local 
interactions between keratinocytes, as well as the adaptive immune response. 
Effective immune detection and surveillance limits overt disease, leading to HPV 
persistence as productive microlesions, or in a true latent state.   
 
 
 
 
 
keywords papillomavirus, epithelial homeostasis, wart, CIN, HPV, infection 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Human Papillomavirus Infection and the Host Response 
 
 As for many viruses that have coevolved with their human hosts, most 
papillomavirus infections are either asymptomatic or inapparent, or lead only to 
the appearance of benign self-limiting lesions that are not life threatening.  This 
balanced relationship ensures survival of the infected host without compromising 
evolutionary fitness, while allowing virus transmission and persistence within the 
population as a whole (1, 2).  To achieve this, papillomaviruses must be delicately 
tuned, both with regard to their effects on the infected cell, as well as their 
interactions with the innate and adaptive immune system – a process that has been 
driven by virus/host co-evolution over millions of years.  In this review, the delicate 
steady state regulation that allows virus persistence in the host, will be considered 
alongside the host events that lead eventually to virus ‘clearance’, or which may 
sometimes allow deregulated viral gene expression and the development of 
neoplasia.  
 
Sexually-Transmitted HPV types and the Diversity of HPV-Associated Disease 
 
 Although the anogenital HPV types attract most attention, much of our 
papillomavirus understanding can be applied more widely to the 200 or so HPV 
types that are known to infect humans (Figure 1).  Human Papillomaviruses are 
divided into 5 phylogenically distinct genera, with the majority residing in the 
Alpha or the Beta/Gamma Genera (3).  The Mu HPV types, which include HPV1, 
contains only 3 members, while only one Nu papillomavirus is known (HPV41).  In 
general, the Beta and Gamma papillomaviruses cause inapparent infections of 
cutaneous epithelial sites.  The Alpha HPV Genera include the well-studied high risk 
types that can be associated with anogeneital and oropharyngeal cancers, but also 
two additional evolutionally branches of low risk papillomavirus that cause cancers 
much more rarely (Figure 1).  Amongst these are cutaneous HPV types such as 
HPV2, that cause common warts in children, and HPV6, which is an important cause 
of genital warts in young adults (1). 
In addition to genital warts, sexually transmitted HPV types (both low and high 
risk) also cause less obvious inapparent infections.  Genital warts are an immediate 
problem, and generally prompt the infected individual to seek treatment.  By 
contrast, inapparent infections are likely to go unnoticed in the absence of 
screening programmes, and in many instances will be effectively resolved by a host 
immune response, and pose no long-term problem.  At particular epithelial sites 
however, infection by high-risk HPV types can be associated with the development 
of neoplasia and sometimes also cancer.   Cervical screening, which is accessible in 
many developed countries, addresses the unique vulnerability of the cervical 
transformation zone region to high-risk HPV-associated neoplasia, and that fact 
that the majority of high-risk HPV-associated cancers occur at this site (4).  The 
general principles that underlie papillomavirus transmission and disease formation, 
and the way that the basic biology of these viruses has been adapted to suit not only 
the sexual transmission route, but also their direct and indirect transmission are 
discussed below.  
 
 
Epithelial Homeostasis and the Maintenance of a Self-Limiting HPV Infection;  
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Papillomavirus Disease-Strategy; It is now generally accepted that HPV infection 
requires virus access to the basal lamina and the epithelial basal cells, and that 
infected basal cells serve as the reservoir of infection to sustain the lesion.  At 
stratified epithelial sites such as the ectocervix, or at cutaneous penile sites, there 
remains a debate as to whether infection of a specialised epithelial stem cell is 
required for lesion formation, or whether papillomaviruses encode particular gene 
functions that modify the infected basal cell to ensure persistence (2, 5, 6).  Clearly 
papillomaviruses have gene functions that limit the ability of the infected basal cell 
to commit to differentiation when compared to neighbouring uninfected cells, a 
process which in itself allows expansion of the infected cell population in the 
infected basal layer (Figure 2) (7, 8).  In the case of the high-risk HPV types, which 
are contained in the Alpha genus, this is a largely E6-mediated function. HPV16 E6 
gene expression is facilitated in the growth factor rich environment of the basal and 
parabasal epithelial layers, with an increase in E6 abundance driving a 
corresponding decrease in p53 activity as a result of E6-mediated proteasome 
degradation (9, 10).  In the epithelial basal layer, this p53 reduction leads to a loss 
of p53 transcriptional activity, which in turn leads to reduced levels of the Notch 
receptor on the cell surface.  Basal cell density and commitment to differentiation 
are critically dependent on normal Notch function, with minor reductions in Notch 
activity providing the cell with a competitive advantage over its neighbours (Figure 
2) (11).  It is likely that some variation on this general theme underlies persistence 
in lesions caused by both high and low-risk HPV types, although the effects on p53, 
and indeed other E6 cellular targets are expected to have subtly different 
mechanisms of regulation.  This can be anticipated by comparison with the 
evolutionarily distinct Beta HPV types, which cause widespread inapparent 
infections at cutaneous sites, and which similarly target Notch, but at a different 
point in the pathway (12, 13).  Of course, papillomaviruses need not only to control 
the rate of cell loss through differentiation, but also the replication of their own 
genomes in the infected basal cell.  Not surprisingly, studies using model systems 
have suggested that HPV genome copy number is linked to the replication of 
cellular DNA in the epithelial basal layer, with viral episomes persisting at a 
constant low level (14).  Although most of the DNA replication machinery that the 
virus requires is provided by the basal cell, it is though that HPV genome 
persistence is critically dependent on the viral E2 protein, which amongst its 
various roles, is involved in HPV genome partitioning as the infected cell divides 
(15).  
 
 Given that papillomaviruses are epithelial specialists, it is perhaps not surprising 
that they interfere with the regulatory pathways that control cell expansion and cell 
density in the epithelial basal layer, and that they generally do this in a very 
ordered way that results in a self-limiting infection (16, 17).  Once a basal cell has 
become infected, it is not easily lost from the body, even as genetic errors 
accumulate.  The difficulty in eradicating HPV infections, including verrucas, 
common warts and genital warts, is likely to stem from the common characteristics 
of the infected basal cells, and that a lesion can be ‘rebuilt’ if even a small number of 
infected basal cells remain (Figure 2) (11).  An effective immune response to viral 
gene products is thus of great importance for effective disease control and 
clearance. 
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The Basal Reservoir Maintains a Supply of HPV Infected Cells for the 
Differentiated Epithelial Layers  
 
 Although not necessarily complete, the above description outlines the 
fundamental strategies on which papillomavirus infections are built.  It appears that 
the high and low-risk Alpha HPV types, and the Beta HPV types exhibit variations 
on the theme rather than following a completely distinct approach (18).   These 
differences reflect the characteristic disease biology and tropisms of each HPV 
genus and type. 
 
 Completion of the productive stages of the HPV life cycle, depends on the steady 
flow of infected cells from the basal layer reservoir into the upper epithelial layers 
(Figure 3).  During this process, local growth factor stimulation declines, 
extracellular signals driving differentiation increase, and the patterns of viral gene 
expression change, in order to favour viral genome amplification over viral 
persistence.  Although not yet mapped in great detail, this involves changes in viral 
promoter usage and changes in mRNA splicing, and the expression of additional 
viral gene products that facilitate life cycle completion.  Here, the E7 protein 
specialises in driving cell cycle re-entry in cells of the parabasal and mid epithelial 
layers in order to provide the cellular replication machinery required for viral 
genome amplification (19).  To a large extent, this is achieved by association with 
members of the retinoblastoma family of proteins (particularly p130), which 
releases the E2F transcription factor to allow progression into S-phase.  The 
broader retinoblastoma specificity of the high risk E7 proteins (which includes 
p105 and p107) is though to contribute to their ability to drive cell cycle entry in 
both the basal and suprabasal layers – a characteristic not shared by low-risk HPV 
types (20).  In these epithelial layers, E6 may still be required to suppress p53 
function, which would otherwise be enhanced by E7.  Curiously, the elevation of E5 
predicted in these epithelial layers, acts to mimic growth factor stimulation by 
constitutively activating the Epidermal Growth factor receptor despite the absence 
of ligand (21).  This is thought to enhance the expression of full-length E6 protein, 
as well the post-translational modification of E1, a virally encoded DNA helicase 
necessary for viral genome amplification.   In fact, the timely elevation of E1 and E2 
in cells that are driven into S-phase by E6 and E7, is key to increasing viral genome 
copy number in preparation for packaging (22).   
(23) 
 Genome amplification and the subsequent increase in gene expression, also 
provides an environment in which the HPV late promoter can be activated, allowing 
the production of the E1^E4, L2 and L1 proteins.  The L2 protein associates with E2 
transiently during genome packaging, but is also (unlike E2) a minor component of 
the icosahedral capsid.   Papillomavirus particles consist of 360 L1 molecules 
arranged in 72 pentomeric capsomeres, with a variable number of L2 molecules, 
which are present at the centre of the capsomeres (24). The most abundant viral 
protein by far is E1^E4 which assembles into keratin-associated amyloid fibres in 
the mid to upper epithelial layers.  Although not part of the infectious particle, the 
E1^E4 amyloid structures are though to enhance virus release, and may also 
contribute to virus stability and transmission.  Productive infection depends 
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therefore on the co-ordinated expression of a number of viral proteins during the 
process of epithelial differentiation.  As discussed later, the success of this process 
depends on the nature of the infecting HPV type, the epithelial site of infection, but 
also the host response to infection, and in particular whether an adaptive immune 
response is raised to control infection.   
 
 
 Levels of Human Papillomavirus Control by the Host Immune System 
 
 A key suggestion from the above, is that mechanical pressure brought about by 
cell to cell contact can limit papilloma lesion size, at least in situations where viral 
gene expression is appropriately regulated.  The self-limiting warts and verrucas 
caused by low risk HPV types are likely to be regulated in part by these mechanisms.  
It is clear however, that both the adaptive and the innate immune system are also 
critically important in limiting the extent of new infection and spread, and that 
immune deficiencies can facilitate deregulated viral gene expression and viral copy 
number elevation. 
 
Preventing Infection; Early studies using model systems of disease have clearly 
shown that prior-immunisation with papillomavirus particles or papillomavirus 
‘virus-like particles’ (VLP) can protect against subsequent challenge (25, 26).  This 
protective effect is mediated by neutralising antibodies to the viral capsid proteins, 
with inflammation and local antibody levels rising at sites of tissue damage.  In 
most cases, disruption of the epithelial barrier is necessary to allow papillomavirus 
access to the basal layer, a situation that can also facilitate virus neutralisation in 
vaccinated individuals.  In fact, a key limitation of HPV VLP vaccination, arises from 
the antigenic diversity apparent amongst the structural proteins of different HPV 
types, with HPV genotype divisions resembling the divisions that might also be 
expected on the basis of serology.  In order to protect the 8kb viral genome, and to 
assemble into pentomeric capsomeres and infectious virus particles, much of the 
structure of the L1 molecule must however be conserved.  The regions of L1 that 
are displayed on the virus surface can vary greatly between HPV types however, 
with the L1 protein having 5 hypervariable surface loops, which act to limit the 
production of cross-neutralising antibodies following HPV immunisation or natural 
infection (23).  The rapid evolution of coat protein diversity is well characterised 
amongst RNA viruses such as Influenza A and Norovirus, where the error-prone 
replication of RNA genomes maintains a pool of antigenically diverse viruses in the 
population that can infect the same host repeatedly.  For papillomaviruses, which 
have a slower mutating double stranded DNA genome, it appears that the host 
immune system has driven the appearance of multiple co-existing HPV types, that 
have diverged in their immunogenicity, but which have similar tropisms and 
disease-associations (3, 27).   HPV2, 57 and 27, which cause common warts in 
children, are an example of this from the low-risk cutaneous Alpha 
papillomaviruses, with HPV16, 31, 33 and 35 forming a similar group amongst 
high-risk ‘mucosal’ types.   At a population level, it appears that the host immune 
responses that occur in individuals during virus exposure and infection, contribute 
to the maintenance of HPV diversity in the wider general population, allowing 
individuals who have already cleared one HPV type to be infected with another.  
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As outlined above, vaccine studies have clearly shown us that a potent 
antibody response can protect against infection.  During natural infection however, 
only low virus titres are required at the basal lamina, and because newly assembled 
HPV virions are in general produced only in the upper epithelial layers, the humoral 
immune response to viral capsid during natural infection can be highly variable 
(28). Vaccination, which involves the intramuscular injection of VLP and adjuvant, 
always produces a more potent immune response.  In the case of persistent ongoing 
infections, the extent to which further infection by the same HPV types is inhibited, 
will depend on the extent of the anti-viral antibody response.  Once an infection has 
been cleared as a result of a cell-mediated immune response, we would expect 
protection against new lesion formation, or at the very least, effective control of 
such infections as described below. 
 
Controlling the Spread of Disease Following Infection; Once infection has 
occurred, the process of lesion formation can begin.  Our current knowledge of how 
viral gene expression is regulated during this process is at present quite limited.  In 
animal models of disease, lesion formation takes four weeks or so depending on 
infectious titre, with microlesions being apparent by histology after two weeks, and 
the first signs of L1 and L2 capsid protein expression being seen at three weeks 
post-infection.  Our current hypothesis suggests that papillomaviruses have a 
limited ability to increase the growth rate of infected cells during the initial stages 
of wound healing, and act instead to prevent cell cycle exit and G0-progression as 
cell density increases (11, 16). In an immune competent host, both low and high-
risk HPV types can persist for months or years, causing chronic productive lesions 
that shed virus from their surface layers over a prolonged period of time.   To 
achieve this, papillomaviruses have a number of key adaptations (described below), 
which allow them to persist in infected epithelial cells, even in the face of an active 
adaptive immune system.   
 One of the key ways in which papillomaviruses avoid immune detection, is by 
limiting viral gene expression in the epithelial basal and parabasal layers to very 
low levels.  This is possible because only low-levels of just a small number of viral 
proteins are required for basal cell genome maintenance, a situation that restricts 
the presentation of viral antigens on MHC class 1 and the stimulation of adaptive 
cell-mediated immunity.   In fact, for many low-risk HPV types, viral gene 
expression in the epithelial basal cell has been extremely difficult to detect.  The 
elevated viral gene expression that is essential for viral genome amplification and 
virus synthesis, is typically delayed until the infected cell reaches the mid or upper 
epithelial layers where T-cells and dendritic cells are less abundant, and where 
immune surveillance is thus less efficient.  In addition, some but not all HPV types 
contain a short E5 gene between the early and late regions of the viral genome (21).  
E5 can contribute to viral genome amplification through the constitutive activation 
of MAPK signalling, but E5 also inhibits the presentation of viral peptides on MHC 
class 1 as a result of MHC down-regulation (29).  Although this model is well 
accepted, and applies to the medically important Alpha HPV types and also to some 
animal papillomaviruses (e.g. BPV), not all HPV types encode an E5 protein, with E5 
being conspicuously absent in the Beta and Gamma HPV Genera (18).  Furthermore, 
in lesions caused by a few HPV types, including the plantar/palmar warts caused by 
HPV1 (Mu Genus) and HPV65 (Gamma Genus), the viral E4 protein can become 
abundantly expressed in the first parabasal cell layers of the epithelium, and can 
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sometimes be additionally detected in a subset of cells in the basal layer itself, 
presumably in cells that have committed to differentiation (30).  These 
observations almost certainly reflect the different life-cycle strategies used by 
different HPV types, with some such as HPV16, and probably also other Alpha HPV 
types such as HPV11 and HPV2, actively inhibiting MHC antigen-presentation to 
produce the more conspicuous lesions.  Others, including the Beta and Gamma 
types that typically cause wide-spread, chronic, but ‘generally asymptomatic’ 
lesions in immunocompetent individuals, appear to be better served when a 
controlled immune response is mounted.  This allows long-term virus shedding, but 
not the clearance of viral genomes from the infected basal layer (31).  Curiously, Mu 
papillomaviruses and a subset of Gamma HPV types, cause visible lesions only at 
particular epithelial body sites.  The most notable of these are the soles of the feet, 
with individual HPV1 verrucas containing as many as 1 x 1012 virus particles, and 
accumulating E4 to levels as high as 30% of total lesional protein content (32). 
 In addition to down-regulating canonical MHC class 1 levels, an approach that is 
also employed by other viruses(33), papillomaviruses may also retard the adaptive 
immune response by inhibiting the retention of Langerhans cells at the site of 
infection. HPV-infected tissue typically has a lower Langerhan cell density that the 
surrounding uninfected epithelium (34, 35). Langerhans cells are epithelial-specific 
dendritic cell, that can display foreign peptides on their surface-MHC class 2, and 
facilitate the activation of a T-cell response following lymph node migration. 
Because papillomaviruses do not stimulate a lytic infection however, and because 
they shed virus particles only from the epithelial surface, the opportunity for 
Langerhans cells to sample and appropriately present viral antigens is severely 
restricted.  Even so, lesion regression, when it eventually occurs, appears to depend 
on the cross-priming of epithelial-specific dendritic cell with viral antigens, and the 
subsequent activation of a T cell response in the draining lymph node (36).  It is 
generally thought that these virus-specific defences, by stalling the adaptive 
immune response, act to prolong the duration of infection. 
 
The Immune Response Controls Chronic Infection and Latency, and can lead to 
Clearance; Most high risk HPV infections eventually clear as a result of a host cell-
mediated immune response in under 18 months, with effective immune recognition 
leading to T-cell homing and T-cell infiltration at the site of infection (Figure 4).  
The limited availability of animal models in which to study PV biology, has meant 
that the process of immune regression is still not well understood.  According to 
current thinking, lesion infiltration by HPV-specific CD4/CD8-positive T-cells does 
not necessarily control disease through cytotoxic killing of virus-infected cells.  
Instead, it has been suggested that viral gene expression, and thus the visibility of 
infected cells to the immune system, becomes actively suppressed as infiltration 
occurs, a process that is mediated by changes in the cytokine milieu that 
accompanies the regression process (Figure 4). HPV-specific helper CD4 T cells that 
are able to recognise epitopes on the HPV E2 and E6 proteins have been reported to 
be important in the ‘clearance’ of low-grade HPV-induced disease (37, 38), with a 
CD4 response to E7 being more important in the control of high-grade neoplasia 
(39). Clearly, the precise nature of the host response to infection depends on which 
viral antigens are seen by the immune system, as well as the time-period between 
infection and eventual immune-detection.  Importantly, the very low levels of viral 
antigen expressed in the basal epithelial cells, particularly in productive low-grade 
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disease, is thought to render these cells effectively ‘invisible’ to the immune system, 
even after a successful antiviral response has been mounted and visible disease has 
been cleared.  The concept of genome maintenance in the absence of significant 
viral gene expression underlies our concept of viral latency, and the immunological 
mechanisms that allow chronic inapparent active HPV infection and the long-term 
shedding of virus particles from apparently normal epithelial tissue (40). Indeed, 
chronic inapparent infection is the life cycle strategy favoured by the Beta and 
Gamma HPV genera that are ubiquitously present at many epithelial surfaces.  It is 
though that a comparable immune control can also operate after the immune 
regression of productive lesions caused by high-risk Alpha HPV types such as 
HPV16, or the conspicuous genital and common warts caused by HPV 11 or 2. 
 To understand the process of immunosurveillance further, it is worth noting that 
in addition to Langerhans cells, there is also a significant population of skin-
resident T cells in the basal and parabasal epithelial layers, with the total number of 
T-cells at this location being actually higher than in the blood (41, 42).  In humans, 
these are predominantly α/β TCR+ memory T cells, that can undergo immediate 
clonal expansion when viral antigens are seen (43).  Studies on other viruses 
(notably HSV) have shown that dendritic cell-mediated antigen presentation to 
memory CD8+ T cells, in the presence of CD4+ T cells in the skin, leads to rapid T-
cell proliferation in the absence of lymphatic organ involvement (44).  Infection 
with vaccinia virus can similarly stimulate the generation of protective long-lived 
non-recirculating CD8+ memory cells that can be found throughout the skin (45), 
and it is appears the skin-resident memory T cells play an important role in limiting 
the extent of HPV infection also.  In fact, in many cases, we should regard visible 
productive papillomas, inapparent infections, microlesions, and true 
papillomavirus latency, as variations on a theme rather than distinct entities.  
Conspicuous   productive infections can thus persist in the absence of an effective 
immune response, a situation that is further compounded by the immune evasion 
capabilities of E6, E7 (see below) and E5 (see above).   Following immune detection 
however, such active infection is suppressed, with the level of control being 
dependent on the ability of skin resident memory T cells to recognise the occasional 
infected basal cell that manage to support genome amplification and virus synthesis.  
Clearly there is a balance between the potency of the host immune response, and 
the viruses ability to stimulate host immunity at low level over a prolonged period 
of time, while still producing sufficient virus into the environment.  Any reduction 
in the level of immunesurveillance, such as may occur during aging or following 
treatment with immune suppressive drugs, can allow more extensive viral gene 
expression, and even the appearance/reappearance of papillomas or neoplasia (40, 
46, 47). 
 In the context of the above, there is an ongoing discussion as to whether immune 
regression leads predominantly to latency, a situation where the viral genome may 
persist in the epithelial basal cell without being seen by the immune system, or 
whether true clearance of viral genomes from the basal layer can also occur.  
Clearly, viral genome maintenance is sensitive to the basal cell environment, with 
viral genome copy number declining in response to type 1 interferons, which 
suggests that basal cell copy number may be affected indirectly during the process 
of regression (36). Indeed, keratinocytes themselves can secrete IFNκ, a type 1 IFN 
(48), as well as a range of proinflamatory cytokines and chemokines in response to 
virus infection, which is expected to recruit immune cells, including NK cells to the 
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site of infection.  In many cases, it appears that HPV gene products can however 
render the infected cell less sensitive to these local changes, and can also inhibit 
innate immune responses within the cell.  The E6 and E7 proteins, at least in the 
case of high-risk HPV types, disrupt the type 1 Interferon response by inhibiting 
both STAT phosphorylation and their nuclear accumulation(49).  In addition, high 
risk E6 can disrupt the function of Tyk2, an immediate downstream component of 
the interferon signalling pathway, with E7 inhibiting IRF 1 (Interferon response 
factor 1), a transcription factor directly involved in the induction of interferon 
stimulated genes (49).  In addition, E7 inhibits MHC presentation by repressing 
LMP2 and TAP1, and reduces the levels of MHC class 1 heavy chain, which along 
with E5, contributes to the general loss of MHC class 1 on the cell surface. NK killing 
is avoided because non-canonical MHC levels are thought to be unaffected, and 
because the E5 protein can also down regulate at least some of the signals required 
for NK activation (50). In most cases, these functions are only established for the 
high risk Alpha HPV types, although we also expect some functional conservation 
amongst the low risk Alpha papillomaviruses.  Importantly, immune evasion is 
unlikely to be required solely in the infected basal cell, where viral gene expression 
is low.  Similarly, the intracellular detection of viral DNA by the pattern recognition 
receptors may be less important in the epithelial basal layer, where only low copy 
numbers of double-stranded nuclear HPV episomes are present.  A more 
conspicuous requirement is expected during viral genome amplification, where 
copy number per cell can rise 10,000 fold.  Even so, it has been suggested that the 
HPV genome can activate the RIG-1-like (RLR) and STING/cGAS pathways that 
detect cytoplasmic dsDNA, as well as endosomal toll-like receptor (TLR) pathways 
(51), and that these innate defences against viral genomes are countered by the 
activity of HPV encoded genes (E6, E7 and E2).  The question as to whether host 
immune responses can clear viral genomes from the epithelial basal layer still 
remains the subject of speculation, but it is reasonable to expect this in some 
instances.  Indeed, in the ROPV (Rabbit Oral Papillomavirus) model of PV latency, 
viral genomes are cleared slowly from the epithelial basal layer following 
regression, which could be explained by stochastic process of cell division and cell 
loss through differentiation.  Interestingly, it may be the precise nature of the 
adaptive immune response, and the relative predominance of CD4+ helper T cells 
vs. CD8+ cytotoxic T cells that determine the precise outcome of infection, as has 
been suggested from studies on MmuPV (52). 
  
Failure to Control Infection allows Chronic Deregulated Gene expression, and 
the Development of Neoplasia and Cancer 
 
Disease persistence corresponds with a failure of the immune system to properly 
detect infection, and is generally characterised by only low numbers of circulating 
antigen-specific T cells and an abundance of CD25-positive T-regulatory cells, 
which produce an intraepithelial cytokine milieu that restricts T cell trafficking.  
Interferon gamma levels are low, and anti-inflammatory cytokines such as IL10 and 
TGF-β are elevated, inhibiting the local proliferation and differentiation of the CD4 
and CD8-positive T cells that might otherwise control infection (36).  In this 
immune-tolerant environment, disease persistence is facilitated, and deregulated 
viral gene expression can go unchecked.  For the high risk Alpha HPV types, the loss 
of control of key HPV genes, particularly the E6 and E7 genes that regulate cell cycle 
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entry, cell proliferation, and differentiation leads to a dramatic change in lesion 
phenotype (53).  During the ordered productive life cycle, these genes are carefully 
regulated, and act to subtly control the basal cells commitment to differentiation, 
and the suprabasal cells ability to enter the cell cycle for genome amplification.  As 
their expression increases in the basal layer, normal cellular controls are 
progressively compromised, leading to neoplasia (e.g. CIN1, 2 and 3), with the 
ability of the virus to complete its life cycle and to produce infectious virions at the 
epithelial surface being progressively lost.  Progression to high grade neoplasia it 
seems, is advantageous for neither the virus nor the host.  In fact the situation is 
exacerbated, because the viral proteins that drive neoplastic progression (i.e. E6 
and E7), at least amongst high risk HPV types, also contribute to immune evasion 
(36).  As a result, increased high risk viral gene expression does not result in 
increased immune visibility.  For the low risk Alpha HPV types, the regulation of E6 
and E7 is differently controlled and involves two separate promoters.  The effects 
on p53 and Rb are differently regulated, and their contribution to immune evasion 
less clearly defined.  As a result, the propensity of low risk HPV types to cause 
neoplasia and cancers appears to be very low, and is often considered to be 
negligible in the general population.  However, the concept of persistent 
deregulated viral gene expression as a general cause of HPV-induced cancers 
extends beyond just the extensively studied high risk Alpha group.  The ubiquitous 
Beta and Gamma HPV types can cause non melanoma skin cancer in individuals 
who are immune compromised, and in these situations, it is clear that deregulated 
viral gene expression can be seen.  Even the low risk Alpha HPV types such as 
HPV11 can cause cancers in individuals who are persistently infected and who 
cannot properly control their active infections.  The cancers associated in 
individuals suffering from recurrent respiratory papillomatosis clearly attest to this 
(54).  In each case, cancer development takes time, and is associated with the host’s 
inability to keep a check on viral gene expression.  The unique organisation of the 
high risk HPV genome, coupled with the curious additional functions encoded by 
their E6 and E7 genes, means that it is these HPV types that are responsible for 
most of the HPV-associated cancer burden. 
 
 
HPV Induced Cancers Occur at Vulnerable Epithelial Sites   
 
Although high risk HPV types can cause cancers at various epithelial sites, including 
the penis, vagina and vulva, the cervical and anal transformation zone, and the 
oropharynx are very clearly hot spots.  Of the 600,000 invasive cancers caused by 
HPV in 2012, invasive cervical cancer constitutes 500,000 or so cases, with other 
anogenital cancers accounting for the bulk of the remainder (data from GLOBOCAN 
2012: http://globocan.iarc.fr/). Oropharyngeal cancers and cancers of the oral 
cavity constitute around 40,000 cases/year.  Cancers caused by HPV are lower in 
men (~1%) than in women (~8.6%), primarily because of the unique vulnerability 
of the cervix uteri to HPV carcinogenesis (55, 56) (Figure 5).  Although a full 
molecular understanding of site-specific vulnerability is not yet available, our 
current thinking is that these epithelial sites lack the protective layers of 
differentiating cells that characterise the external epithelium, but that in addition, 
these particular sites contain specialised epithelial cells that are not able to support 
the productive HPV life cycle.  At the tonsillar crypts, it is the loosely structured 
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reticular epithelium that is the site of high risk HPV-associated neoplasias, rather 
than the more differentiated epithelium that lines the outer tonsillar surface.  The 
unique characteristics of the tonsillar crypt can facilitate pathogen recognition by 
the immune system, but also enhanced virus infection in situations where the 
infected cells are not effectively recognised.  A similar situation occurs at the 
squamocolumnar junction of the cervical and anal transformation zones, where 
stratified epithelial cells abut a columnar epithelium that is more vulnerable to 
infection.  For the cervical transformation zone, the particular vulnerability for the 
development of high risk HPV-associated neoplasia is though to result from the 
presence of a unique type of epithelial cell known as the cervical reserve cell, that 
normally gives rise to either the columnar epithelium of the endocervix and cervical 
glands, but also under some circumstances, can give rise to the stratified cells of the 
cervical transformation zone (Figure 5) (57, 58).  The epithelial changes that allow 
reserve cell to form a stratified transformation zone typically occur at puberty as 
the endocervical cells become exposed to the more acid environment of the vagina.  
Such metaplastic changes can however occur throughout a woman’s life whenever 
the conversion of columnar endocervical epithelial cells to a multi-layered 
epithelium is required.  A second group of vulnerable cuboidal cells have also been 
identified more precisely at the squamocolumnar junction (59).  According to these 
models, viral gene expression is deregulated at these specific sites following 
infection, with an abortive rather than productive viral infection ensuing. It is clear 
that future work needs to consider not just viral protein function, but function and 
gene expression in the context of particular epithelial sites. 
 
Summary 
 
It is apparent from the above, that the majority of human papillomaviruses persist 
quietly within the human population, a situation that fits very well with their 
coevolution with their human hosts over millions of years.  To achieve this, they 
delicately modify epithelial homeostasis upon infection, and set up a regulatory 
balance that allows persistent chronic infection without clearance.  As part of their 
life cycle however, papillomaviruses require genes that drive cell cycle entry, in 
order to allow efficient viral genome amplification and virus particle production.  In 
most cases, these genes are carefully regulated and their effects on cell proliferation 
and differentiation limited.  In humans, an evolutionary branch within the Alpha 
Genus has lead to the appearance of a ‘high risk’ subgroup, that can more 
dramatically affect epithelial basal cell function, even in immune competent hosts.  
This is a consequence of changes in the way that viral gene expression is regulated 
in high risk types, and from the acquisition of viral protein functions that impact on 
epithelial differentiation, the regulation of basal cell proliferation and cell density, 
and the ability to evade immune detection.  Even so, cancers associated with high 
risk types are focused on particular epithelial sites, including the oropharynx and 
the anal and cervical transformation zones.  At present, cervical cancer accounts for 
the vast majority of HPV-associated cancers, prompting the drive to better 
understand the target epithelium as well as the virus. 
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Research Agenda 
 
• To understand how cell type and cell characteristics determine disease 
outcome. 
• To characterise the molecular events that control lesion formation and 
lesion size. 
• To understand the molecular processes underlying the development of 
neoplasia at vulnerable epithelial sites. 
• To explain how the adaptive immune system drives lesion-regression and 
allows persistence as a latent infection. 
• To establish the minimal level of viral gene expression required for basal 
cell persistence, and how viral gene expression changes during 
reactivation.  
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Figure Legends 
 
Figure 1.  Papillomavirus Diversity 
 
A.   The HPV types found in humans fall into five genera, with the Alpha and the 
Beta/Gamma genera representing the largest groups.  HPV types from the Alpha 
genus are often classified as low-risk cutaneous (grey), low-risk mucosal 
(orange) or high-risk (pink).  The high-risk types identified using red text are 
confirmed as ‘human carcinogens’ on the basis of epidemiological data. The 
evolutionary tree is based on alignment of the E1, E2, L1 and L2 genes (60). 
 
B.   Typical genome organisation of the high-risk Alpha, Mu and Beta HPV genomes.  
While all share a common genetic organisation, the size and position of the major 
ORFs can vary.  The positions of the major promoters are marked with arrows 
with early and late polyadenylation sites being marked as PAL (late) and PAE 
(early). 
 
Figure 2.  Papillomaviruses, Epithelial Homeostasis and Self-Limiting Disease 
 
A.   In the uninfected epithelium, proliferating progenitor cells increase basal cell 
density.  Increasing cell density triggers a subset of basal cells to commit to 
differentiate. These cells are lost from the basal layer, so maintaining basal cell 
numbers. 
B.   Both uninfected and low risk HPV-infected progenitor cells are thought to 
behave similarly during cell division.  For low risk HPV types and high risk HPV 
types at some epithelial sites, viral gene expression is thought to result in 
infected cells that are more resistant to cell-cell contact and cell differentiation 
signals.  As a result, HPV infected cells persist in the epithelial basal layer as cell 
density increases. 
C.    Delayed commitment to differentiate and sustained cell proliferation can 
result from deregulated high risk HPV gene expression, and is manifest clinically 
as a neoplasia. 
 
Figure 3. Patterns of Viral Gene expression in the Infected Cervix 
 
The different patterns of viral gene expression associated with different grades of 
neoplasia are illustrated in the cartoons.  Although the diagrams indicate the 
patterns seen in cervical neoplasia, it is though that similar patterns of 
deregulated gene expression underlie neoplasias at other differentiating  
epithelial sites. 
 
 
Figure 4.   Role of the Adaptive Immune System in Controlling infection 
 
1. Active Infection.  Active papillomavirus infection involves the regulated 
expression of viral proteins as cells containing viral genomes migrate towards 
the epithelial surface. Resting T-cells (brown circular cells) and Langerhans cells 
(orange) can be found in the lower layers of the epithelium and in the dermis.   
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2. Immune Regression.  Immune regression involves the presentation of viral 
antigens to the immune system, and the subsequent accumulation of activated 
CD4+ and CD8+ T-cells (light blue circular cells) in and around the lesion.  During 
regression, activated T-cells accumulate within and beneath the lesion. 
3. Latency.  Lesion clearance involves the suppression of viral gene expression as 
lymphocytes infiltrate, and may involve changes in cytokine activity and cytokine 
signaling at the site of regression.  
4. Reactivation from Latency. The presence of memory T-cells circulating in the 
epithelium prevent extensive viral gene expression and keep the viral genomes 
in the basal layer in a latent state.  Changes in immune status would allow local 
rises in viral copy-number. 
 
 
Figure 5.  Vulnerable Epithelial Sites and HPV Cancer Risk 
 
A.   Cervical Intraepithelial Neoplasia (CIN) of different grades are thought to be 
associated with different patterns of viral gene expression.  The viral E4 
protein is shown in green.  The cellular MCM protein is regarded as a surrogate 
of E6/E7 expression in such lesions and is shown in red. 
B.   The cervix is thought to contain a number of different cell types that are 
vulnerable to infection.  Infection outcome is thought to be influenced 
according to the characteristics of the infected cell and the local epithelial 
environment.  Infection of the reserve and cuboidal cells is connected to the 
development of high grade disease. 
C.   Of all the epithelial sites that high risk HPV types can infect, the cervix 
appears uniquely vulnerable, with the vast majority of HPV-associated cancers 
occurring at this site.  Of the infectious agents associated with human cancers, 
HPVs are the most significant.  
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• Most papillomaviruses are associated with asymptomatic infections, or 
self-limiting benign papillomas. 
• The papillomavirus E6 protein restricts the infected basal cells ability to 
commit to differentiation. 
• Viral gene expression is required at very low level in the infected basal 
layer. 
• The viral E6/E7 proteins are deregulated in high grade neoplasia, and are 
involved in immune evasion. 
• Papillomavirus disease is controlled by immune surveillance by skin-
resident T cells 
